Can you guess the (lightly disputed) champion of healthcare AI suppliers? Here’s a hint. This company caters to physicians and just this week reached a valuation of $12B. 

2026 may be the year that many if not most healthcare leaders arrive at a fork in the road to mature AI implementation. 

Just because a healthcare AI product gets loudly promoted doesn’t mean its claims are bogus. The salient question is whether or not it performs as well in a clinical setting as it did in a research lab—or in a marketer’s mind. 

Across industries, more than a third of the time saved by AI gets eaten by overstretched humans who have to clean up the technology’s sloppy work. 

The FDA wants designers of goods in two health-tech categories to worry more about supplying innovative products than about pleasing the FDA. 

AI is an icy landslide sweeping through healthcare. Even surgeons must choose between two stark options: Ride the crest of the powder cloud now or dig yourselves out of a deep runout zone later. 

During a recent segment on Fox Business, Food and Drug Administration Commissioner Martin Makary, MD, clarified new guidance on AI, meant to provide companies with the flexibility to gather and provide data without the agency's approval. However, medical devices that provide "clinical-grade" data will still need to be cleared.

If you still think of large-language AI as a newish thing yet to catch on with healthcare consumers, think again.